Thrombolysis for acute stroke in Australia: Outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002-2008)

Medical Journal of Australia

Volumn 193, Issue 8, 2010, Pages 439-443

  Simpson, Marion A ^a   Dewey, Helen M ^a,b   Churilov, Leonid ^b   Ahmed, Niaz ^c   Bladin, Christopher F ^d,e   Schultz, David ^f   Markus, Romesh ^g   Sturm, Jonathan W ^h,i   Levi, Christopher R ^j,k   Blacker, David J ^l,m   Jannes, Jim ^n,o,p   Lindley, Richard I ^q   Parsons, Mark W ^j,k  

^a AUSTIN HEALTH   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MONASH UNIVERSITY   (Australia)

^e BOX HILL HOSPITAL   (Australia)

^f FLINDERS MEDICAL CENTRE   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h GOSFORD HOSPITAL   (Australia)

ⁱ Wyong Hospital   (Australia)

^j UNIVERSITY OF NEWCASTLE   (Australia)

^k JOHN HUNTER HOSPITAL   (Australia)

^l SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^m UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁿ QUEEN ELIZABETH HOSPITAL   (Australia)

^o UNIVERSITY OF ADELAIDE   (Australia)

^p SA Health   (Australia)

^q UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIHYPERTENSIVE AGENT; GLUCOSE;

ADULT; AGED; ALLERGY; ANGIONEUROTIC EDEMA; ARTICLE; ASYSTOLE; AUSTRALIA; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN RADIOGRAPHY; COMORBIDITY; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HEMOPERITONEUM; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANKIN SCALE; REGISTER; RISK FACTOR; STROKE;

EID: 78149336330     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03996.x     Document Type: Article

References (21)

1. Bray JE, Coughlan K, Bladin C. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern Med J 2006; 36: 483-488. (Pubitemid 43990899)
2. Szoeke CE, Parsons MW, Butcher KA, et al. Acute stroke thrombolysis with tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-328. (Pubitemid 36503093)
3. Quain DA, Parsons MW, Loudfoot AR, et al. Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care. Med J Aust 2008; 189: 429-433.
4. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; (4): CD000213. doi: 10/1002/14651858. CD000213. pub2.
5. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischaemic stroke. N Engl J Med 2008; 359: 1317-1329.
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
7. Kaste M, Thomassen L, Grond M, et al. Thrombolysis for acute ischemic stroke: a consensus statement of the 3rd Karolinska Stroke Update, October 30-31, 2000. Stroke 2001; 32: 2717-2718.
8. Safe Implementation of Treatments in Stroke [website]. https://sitsinternational.org/ (accessed Sep 2010).
9. Wahlgren N, Ahmed N, Dávalos A, et al; SITS Investigators. Thrombolysis with alteplase 3- 4.5 hours after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-1309.
10. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
11. Internet Stroke Center. Stroke scales and clinical assessment tools: NIH Stroke Scale (NIHSS). http://www.strokecenter.org/trials/ scales/nihss.html (accessed Sep 2010).
12. Wahlgren N, Ahmed N, Dávalos A, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282. (Pubitemid 46138121)
13. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
14. National Stroke Foundation. Clinical guidelines for acute stroke management. Canberra: NHMRC, 2007. http://www.nhmrc.gov.au/-files-nhmrc/file/ publications/synopses/cp109.pdf (accessed Sep 2010).
15. National Institute for Health and Clinical Excellence. Alteplase for the treatment of acute ischaemic stroke. London: NICE, 2007. http ://www.nice.org.uk/nicemedia/pdf/ TA122guidance.pdf (accessed Sep 2010).
16. European Stroke Initiative Executive Committee; EUSI Writing Committee. European Stroke Initiative recommendations for stroke management - update 2003. Cerebrovasc Dis 2003; 16: 311-337.
17. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischaemic stroke. Stroke 2007; 38: 1655-1711.
18. Gattellari M, Worthington JM, Zwar NA, Middleton S. The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey. BMC Fam Pract 2008; 9: 62.
19. National Institute of Neurological Disorders and Stroke. NINDS stroke information page. http://www.ninds.nih.gov/disorders/stroke/ stroke.htm (accessed Sep 2010).
20. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischaemic stroke. A meta-analysis. Stroke 2009; 40: 2438-2441.
21. Stroke Foundation. National Stroke Foundation Website statistics on Stroke Unit Care (September 2007). http://www.strokefoundation.com.au/component/ option,com-docman/task,doc-details/Itemid,/gid,278/ (accessed Sep 2010).